TY - JOUR
T1 - Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer
AU - Dahl, Laurits Sebastian
AU - Knoop, Ann Søegaard
AU - Jensen, Maj-Britt
AU - Harder, Eva
AU - Rønlev, Jeanette Dupont
AU - Berg, Tobias
N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.
PY - 2025/9/18
Y1 - 2025/9/18
N2 - INTRODUCTION: Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB trial. In this short report, we evaluate the extent and efficacy of tucatinib treatment among Danish patients.METHODS: This is a retrospective study that includes all known Danish patients who initiated tucatinib prior to June 1, 2024. We utilised the nationwide clinical database of the Danish Breast Cancer.RESULTS: In total, 38 patients were treated. Nineteen (50%) of the patients had central nervous system (CNS) metastases, and 21 (55%) had visceral disease. Median progression-free survival was 8.7 months (95% CI: 6.2; 13.3) and median overall survival was 22.4 months (95% CI: 13.1; N/A). Nine patients exhibited a performance status of 2-3 (n = 5) or uncontrollable CNS metastases (n = 4), not meeting the inclusion criteria applied in the HER2CLIMB trial.CONCLUSIONS: Our results align with data presented from the HER2CLIMB trial. Considerably fewer patients than initially expected have been treated in Denmark.FUNDING: None.TRIAL REGISTRATION: Approved by the Capital Regions Research Overview (P-2024-175774) and the Centre for Health Research (R-24065900).
AB - INTRODUCTION: Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB trial. In this short report, we evaluate the extent and efficacy of tucatinib treatment among Danish patients.METHODS: This is a retrospective study that includes all known Danish patients who initiated tucatinib prior to June 1, 2024. We utilised the nationwide clinical database of the Danish Breast Cancer.RESULTS: In total, 38 patients were treated. Nineteen (50%) of the patients had central nervous system (CNS) metastases, and 21 (55%) had visceral disease. Median progression-free survival was 8.7 months (95% CI: 6.2; 13.3) and median overall survival was 22.4 months (95% CI: 13.1; N/A). Nine patients exhibited a performance status of 2-3 (n = 5) or uncontrollable CNS metastases (n = 4), not meeting the inclusion criteria applied in the HER2CLIMB trial.CONCLUSIONS: Our results align with data presented from the HER2CLIMB trial. Considerably fewer patients than initially expected have been treated in Denmark.FUNDING: None.TRIAL REGISTRATION: Approved by the Capital Regions Research Overview (P-2024-175774) and the Centre for Health Research (R-24065900).
KW - Humans
KW - Breast Neoplasms/drug therapy
KW - Female
KW - Denmark
KW - Retrospective Studies
KW - Receptor, ErbB-2/metabolism
KW - Middle Aged
KW - Quinazolines/therapeutic use
KW - Aged
KW - Adult
KW - Oxazoles/therapeutic use
KW - Pyridines/therapeutic use
KW - Trastuzumab/therapeutic use
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Capecitabine/therapeutic use
KW - Progression-Free Survival
KW - Antineoplastic Agents/therapeutic use
KW - Aged, 80 and over
KW - Treatment Outcome
KW - Central Nervous System Neoplasms/secondary
UR - http://www.scopus.com/inward/record.url?scp=105018280382&partnerID=8YFLogxK
U2 - 10.61409/A11240821
DO - 10.61409/A11240821
M3 - Journal article
C2 - 41069324
SN - 1603-9629
VL - 72
JO - Danish Medical Journal
JF - Danish Medical Journal
IS - 10
M1 - A11240821
ER -